Reproductive dysfunction in hemodialysis: endocrine mechanisms, clinical features, and therapeutic approaches.

Reproductive dysfunction is described as a near-universal complication in patients on maintenance hemodialysis.

• The condition profoundly impacts quality of life in this patient population.
• The review characterizes the core pathophysiology as a 'dual-hit' endocrine collapse.
• Both central suppression of the hypothalamic-pituitary-gonadal (HPG) axis and peripheral gonadal resistance are involved.
• The uremic milieu is identified as the driver of these dual mechanisms.

In male hemodialysis patients, reproductive dysfunction manifests primarily as hypogonadism with erectile dysfunction serving as a sentinel marker for systemic vascular disease.

• Erectile dysfunction is characterized as a 'critical sentinel marker for systemic vascular disease' in this population.
• The dysfunction results from both central HPG axis suppression and peripheral gonadal resistance.
• Hypogonadism is the primary clinical manifestation in men on hemodialysis.

In female hemodialysis patients, reproductive dysfunction results in a reversible menopause-like state characterized by anovulation and infertility.

• The menopause-like state is described as reversible, distinguishing it from true menopause.
• Key features include anovulation and infertility.
• The condition results from the same dual-hit mechanism of HPG axis suppression and gonadal resistance.

Conventional hemodialysis is insufficient to correct reproductive endocrine derangements in dialysis patients.

• Standard hemodialysis regimens fail to adequately clear uremic toxins responsible for HPG axis disruption.
• Intensified regimens such as nocturnal hemodialysis can partially restore fertility.
• Nocturnal hemodialysis was noted to dramatically improve pregnancy outcomes.

Targeted pharmacological interventions including phosphodiesterase-5 inhibitors and hormone replacement therapy are effective for specific indications in hemodialysis patients with reproductive dysfunction.

• Phosphodiesterase-5 inhibitors are identified as effective for specific indications, primarily erectile dysfunction in men.
• Hormone replacement therapy is identified as effective for specific indications in women.
• These therapies are described as practical strategies that can mitigate but not fully correct the underlying endocrine derangements.

Kidney transplantation offers the best chance of restoring normal endocrine function in patients with uremia-related reproductive dysfunction.

• Transplantation is ranked as the most effective intervention for restoring reproductive endocrine function.
• This is attributed to its ability to correct the underlying uremic milieu responsible for the dual-hit endocrine collapse.
• Other interventions only partially mitigate the dysfunction rather than restore normal function.

Future therapeutic directions for reproductive dysfunction in hemodialysis include novel therapeutics targeting the kisspeptin system and wearable artificial kidneys.

• The kisspeptin system is identified as a potential therapeutic target, presumably due to its role in regulating the HPG axis.
• Wearable artificial kidneys are proposed as a means to provide continuous uremic clearance.
• Continuous uremic clearance is hypothesized to better address the uremic milieu driving reproductive dysfunction compared to intermittent hemodialysis.